{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:07:20Z","timestamp":1791389240596,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114001","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:19:44Z","timestamp":1710177584000},"page":"114001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Chemo-immunotherapy with dinutuximab beta in patients with relapsed\/progressive high-risk neuroblastoma: does chemotherapy backbone matter?"],"prefix":"10.1016","volume":"202","author":[{"given":"Patricia","family":"Raiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gambart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Defachelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Thebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Tandonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Proust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Entz-Werle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Ndounga-Diakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Puiseux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Khanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Rouger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Mansuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Benadiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pluchart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Laghouati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau-Couanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114001_bib1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114001_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114001_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan\u2013temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114001_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10002","volume":"40","author":"Gray","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.21568","article-title":"Measuring safety and outcomes for the use of compassionate and off-label therapies for children, adolescents, and young adults with cancer in the SACHA-France study","volume":"6","author":"Berlanga","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2024.114001_bib6","doi-asserted-by":"crossref","first-page":"v901","DOI":"10.1093\/annonc\/mdz394.061","article-title":"Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial","volume":"30","author":"Moreno","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114001_bib7","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting","volume":"35","author":"Park","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0959-8049(94)00509-4","article-title":"A new 123I-MIBG whole body scan scoring method\u2014application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma","volume":"31","author":"Ady","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114001_bib9","article-title":"Sample size calculators","author":"Kohn","year":"2024","journal-title":"Sample Size Calc UCSF CTSI"},{"key":"10.1016\/j.ejca.2024.114001_bib10","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab With GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children\u2019s oncology group","volume":"38","author":"Mody","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.22.01273","article-title":"Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan\/temozolomide\/dinutuximab\/granulocyte-macrophage colony-stimulating factor","volume":"41","author":"Lerman","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib12","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.3390\/cancers15133364","article-title":"Effect and tolerance of N5 and N6 chemotherapy cycles in combination with dinutuximab beta in relapsed high-risk neuroblastoma patients who failed at least one second-line therapy","volume":"15","author":"Lode","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114001_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1041443","article-title":"Dinutuximab beta plus conventional chemotherapy for relapsed\/refractory high-risk neuroblastoma: a single-center experience","volume":"12","author":"Olgun","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114001_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1082771","article-title":"Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma","volume":"13","author":"Wieczorek","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114001_bib15","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114001_bib16","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.22.01630","article-title":"Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: a multicenter, phase I\/II trial","volume":"41","author":"Flaadt","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/pbc.26184","article-title":"Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence","volume":"64","author":"Schumacher-Kuckelkorn","year":"2017","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2024.114001_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1093526617723972","article-title":"Expression of disialoganglioside (GD2) in neuroblastic tumors: a prognostic value for patients treated with anti-GD2 immunotherapy","volume":"21","author":"Terzic","year":"2018","journal-title":"Pedia Dev Pathol"},{"key":"10.1016\/j.ejca.2024.114001_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.21.01375","article-title":"Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy: updated results of a Phase II Study using hu14.18K322A","volume":"40","author":"Furman","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114001_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.10014","article-title":"Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: results from the SIOPEN LTI-trial","volume":"37","author":"Lode","year":"2019","journal-title":"JCO"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:09:48Z","timestamp":1727410188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"alternative-id":["S0959804924001576"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemo-immunotherapy with dinutuximab beta in patients with relapsed\/progressive high-risk neuroblastoma: does chemotherapy backbone matter?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114001"}}